venBio Amends Pharvaris N.V. Ownership Filing, Updates Event Dates

TL;DR

**venBio updated its Pharvaris N.V. ownership filing, signaling ongoing portfolio adjustments.**

AI Summary

venBio Global Strategic Fund III, L.P. and its affiliates, including Corey Goodman and Robert Adelman, filed an amendment (SC 13D/A) on January 25, 2024, updating their beneficial ownership in Pharvaris N.V. They reported a change in the event date to December 6, 2023, and January 24, 2024, related to their holdings of Pharvaris N.V. ordinary shares, par value €0.12 per share. This matters to investors because venBio is a significant institutional holder, and changes in their filing indicate ongoing activity or adjustments to their investment thesis, which could influence market perception of Pharvaris N.V.

Why It Matters

This filing indicates that a major institutional investor, venBio, is actively managing its position in Pharvaris N.V., which can signal their evolving view on the company's prospects.

Risk Assessment

Risk Level: low — This is an amendment to an existing ownership filing, indicating routine updates rather than a new, significant event.

Analyst Insight

Investors should monitor future SC 13D/A filings from venBio regarding Pharvaris N.V. for any significant changes in ownership percentage or stated intentions, as these could indicate a shift in a major investor's confidence or strategy.

Key Numbers

• €0.12 — Par value per share (The par value of Pharvaris N.V. ordinary shares.)

Key Players & Entities

• venBio Global Strategic Fund III, L.P. (company) — the filing entity and beneficial owner
• Pharvaris N.V. (company) — the subject company whose shares are owned
• Corey Goodman (person) — a group member associated with venBio
• Robert Adelman (person) — a group member associated with venBio
• €0.12 (dollar_amount) — par value per ordinary share of Pharvaris N.V.
• David Pezeshki (person) — person authorized to receive notices for venBio Partners, LLC

Forward-Looking Statements

• venBio will continue to be an active, significant shareholder in Pharvaris N.V. (venBio Global Strategic Fund III, L.P.) — high confidence, target: Ongoing

FAQ

From the Filing

0001140361-24-003710.txt : 20240125 0001140361-24-003710.hdr.sgml : 20240125 20240124184112 ACCESSION NUMBER: 0001140361-24-003710 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20240125 DATE AS OF CHANGE: 20240124 GROUP MEMBERS: COREY GOODMAN GROUP MEMBERS: ROBERT ADELMAN GROUP MEMBERS: VENBIO GLOBAL STRATEGIC GP III, L.P. GROUP MEMBERS: VENBIO GLOBAL STRATEGIC GP III, LTD. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Pharvaris N.V. CENTRAL INDEX KEY: 0001830487 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-92181 FILM NUMBER: 24558193 BUSINESS ADDRESS: STREET 1: J.H. OORTWEG 21 STREET 2: 2333 CH LEIDEN CITY: LEIDEN STATE: P7 ZIP: 00000 BUSINESS PHONE: 31 (0)71 203 6410 MAIL ADDRESS: STREET 1: J.H. OORTWEG 21 STREET 2: 2333 CH LEIDEN CITY: LEIDEN STATE: P7 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: Pharvaris, B.V. DATE OF NAME CHANGE: 20201029 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: venBio Global Strategic Fund III, L.P. CENTRAL INDEX KEY: 0001739920 ORGANIZATION NAME: IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 1700 OWENS STREET STREET 2: SUITE 595 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-522-0100 MAIL ADDRESS: STREET 1: 1700 OWENS STREET STREET 2: SUITE 595 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 SC 13D/A 1 ef20019681_sc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Pharvaris N.V. (Name of Issuer) Ordinary shares, par value €0.12 per share (Title of Class of Securities) N69605108 (CUSIP Number) David Pezeshki venBio Partners, LLC 1700 Owens Street, Suite 595, San Francisco, CA 94158 (415) 800-0800 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) December 6, 2023, January 24, 2024 (Date of Event Which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐ Note : Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. N69605108   Page 2 of  8 Pages 1 NAMES OF REPORTING PERSONS     venBio Global Strategic Fund III, L.P.         2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐     3 SEC USE ONLY               4 SOURCE OF FUNDS (SEE INSTRUCTIONS)     WC         5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)   ☐         6 CITIZENSHIP OR PLACE OF ORGANIZATION     Cayman Islands         NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTI